A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI

Nazila Kamaly; Tammy Kalber; Gavin Kenny; Jimmy Bell; Michael Jorgensen; Andrew Miller

doi:10.1039/b910561a

A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI

Nazila Kamaly, Tammy Kalber, Gavin Kenny, Jimmy Bell, Michael Jorgensen, Andrew Miller

Imaging and Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

Abstract

We have synthesized a bimodal lipidic molecule bearing both fluorophore and contrast agent signatures on the same structure in order to create a robust bimodal liposome for both magnetic resonance imaging (MRI) and fluorescence microscopy utility. The dual-modality concept considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable in that anatomical information (MRI) as well as very sensitive localization (ex vivo fluorescence microscopy) of signal, and therefore liposome biodistribution, is obtainable. Bimodal cationic and neutral PEGylated liposomes were formulated using this novel lipid probe and used to label cells in vitro and image human ovarian xenografts in vivo. Tumour signal enhancement was increased by over 6-fold post-administration of the neutral PEGylated liposomes, and was maintained at this level up to the 24 h end-point. Our results showed this lipid to be more effective and sensitive than the single signature paramagnetic lipid Gd.DOTA.DSA at cellular labelling and tumour MRI.

Original language	English
Pages (from-to)	201-11
Number of pages	11
Journal	Organic & biomolecular chemistry
Volume	8
Issue number	1
Early online date	5 Nov 2009
DOIs	https://doi.org/10.1039/b910561a
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/b910561a

Cite this

@article{ba505656e4b64f49b4ee3ea42286957e,

title = "A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI",

abstract = "We have synthesized a bimodal lipidic molecule bearing both fluorophore and contrast agent signatures on the same structure in order to create a robust bimodal liposome for both magnetic resonance imaging (MRI) and fluorescence microscopy utility. The dual-modality concept considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable in that anatomical information (MRI) as well as very sensitive localization (ex vivo fluorescence microscopy) of signal, and therefore liposome biodistribution, is obtainable. Bimodal cationic and neutral PEGylated liposomes were formulated using this novel lipid probe and used to label cells in vitro and image human ovarian xenografts in vivo. Tumour signal enhancement was increased by over 6-fold post-administration of the neutral PEGylated liposomes, and was maintained at this level up to the 24 h end-point. Our results showed this lipid to be more effective and sensitive than the single signature paramagnetic lipid Gd.DOTA.DSA at cellular labelling and tumour MRI.",

author = "Nazila Kamaly and Tammy Kalber and Gavin Kenny and Jimmy Bell and Michael Jorgensen and Andrew Miller",

year = "2010",

doi = "10.1039/b910561a",

language = "English",

volume = "8",

pages = "201--11",

journal = "Organic & biomolecular chemistry",

issn = "1477-0539",

publisher = "Royal Society of Chemistry",

number = "1",

}

TY - JOUR

T1 - A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI

AU - Kamaly, Nazila

AU - Kalber, Tammy

AU - Kenny, Gavin

AU - Bell, Jimmy

AU - Jorgensen, Michael

AU - Miller, Andrew

PY - 2010

Y1 - 2010

N2 - We have synthesized a bimodal lipidic molecule bearing both fluorophore and contrast agent signatures on the same structure in order to create a robust bimodal liposome for both magnetic resonance imaging (MRI) and fluorescence microscopy utility. The dual-modality concept considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable in that anatomical information (MRI) as well as very sensitive localization (ex vivo fluorescence microscopy) of signal, and therefore liposome biodistribution, is obtainable. Bimodal cationic and neutral PEGylated liposomes were formulated using this novel lipid probe and used to label cells in vitro and image human ovarian xenografts in vivo. Tumour signal enhancement was increased by over 6-fold post-administration of the neutral PEGylated liposomes, and was maintained at this level up to the 24 h end-point. Our results showed this lipid to be more effective and sensitive than the single signature paramagnetic lipid Gd.DOTA.DSA at cellular labelling and tumour MRI.

AB - We have synthesized a bimodal lipidic molecule bearing both fluorophore and contrast agent signatures on the same structure in order to create a robust bimodal liposome for both magnetic resonance imaging (MRI) and fluorescence microscopy utility. The dual-modality concept considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable in that anatomical information (MRI) as well as very sensitive localization (ex vivo fluorescence microscopy) of signal, and therefore liposome biodistribution, is obtainable. Bimodal cationic and neutral PEGylated liposomes were formulated using this novel lipid probe and used to label cells in vitro and image human ovarian xenografts in vivo. Tumour signal enhancement was increased by over 6-fold post-administration of the neutral PEGylated liposomes, and was maintained at this level up to the 24 h end-point. Our results showed this lipid to be more effective and sensitive than the single signature paramagnetic lipid Gd.DOTA.DSA at cellular labelling and tumour MRI.

U2 - 10.1039/b910561a

DO - 10.1039/b910561a

M3 - Article

C2 - 20024151

SN - 1477-0539

VL - 8

SP - 201

EP - 211

JO - Organic & biomolecular chemistry

JF - Organic & biomolecular chemistry

IS - 1

ER -

A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this